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Pertussis seroimmunity in mother-neonate pairs and other pediatric age 
groups from Egypt 
 
INTRODUCTION 
Pertussis remains a serious infection in young 
infants. Most deaths occur in the first 3 months of 
life, before administration of the first dose of 
pertussis vaccine. Pertussis antibodies are 
transferred transplacental; but due to the lack of 
serologic correlates of protection, it is difficult to 
estimate the proportion of infants born with a 
protective levels of maternal antibodies.1 
Adolescents and adults have been identified as a 
source of transmission of pertussis to very young 
infants who are unimmunized or partially 
immunized and thus more vulnerable to disease 
morbidity and mortality2  
Despite the widespread availability of 2 classes 
of effective vaccines, whole cell and acellular, 
pertussis has remained endemic and/or re-surged as 
a public health problem in many geographic 
locations. In 2015, the World Health Organization 
reported 142,512 pertussis cases globally, and 
estimated that there were 89,000 deaths. A recent 
CDC report estimates that there were 24.1 million 
pertussis cases and 160,700 deaths in children 
younger than 5 years in 2014 worldwide. 
While Bordetella pertussis circulates worldwide, 
disease rates are highest among young children in 
countries with low vaccination coverage rates, 
primarily in the developing world. In developed 
countries, the incidence of pertussis is highest 
among unvaccinated babies and rises again among 
teens.3 
The international resurgence of pertussis, 
including the increase among the 7 to 10 year olds, 
is probably driven by a number of factors including 
a true return of the disease, increased public 
awareness, and better recognition and reporting by 
physicians, improved laboratory procedures such as 
PCR, and waning of immunity levels. It has also 
been hypothesized that genetic changes in the 
circulating strains of the organism may be a 
contributing factor through increasing vaccine 
failures. Another explanation might be the use of 
acellular component in the DTaP vaccines which is 
less potent than the old DTP vaccine. 4,5  
There is evidence that a true resurgence has 
occurred in 5 countries (Australia, Chile, Portugal, 
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USA and UK), four of which were exclusively 
using acellular pertussis (aP) vaccines. The 
observed increase in cases in Chile, which used 
whole cell pertussis (wP) vaccine, was considered 
to be related to factors other than the vaccine type, 
such as changes in surveillance and laboratory 
methods, and a recent decline in vaccination 
coverage.6 
Among Egyptian children a positive trend in 
DPT immunization coverage was observed over the 
past years. It was significantly correlated with the 
reduction in the number of recorded cases, and 
since 2003 there were no recorded cases in Egypt as 
reported by the Ministry of Health and Population 
in 2005.7 However, there are no recently published 
data on pertussis infection rates among the Egyptian 
population. 
Waning of vaccine-induced immunity has been 
cited as one of the reasons for the observed 
epidemiologic trend. Naturally acquired immunity 
was reported to be persist for 7-20 years while 
vaccine-induced immunity remains valid for 4–12 
years.8  
Although pertussis vaccination is obligatory in 
Egypt, the recent emergence of whooping cough in 
other parts of the world stimulated us to investigate 
the current immune status against pertussis in in the 
pediatric age groups and in mother-neonate pairs. 
The ultimate objective is to trace any possible 
susceptibility of Egyptians to this devastating 
infectious disease and anticipate the need for further 
booster immunization.  
  
METHODS 
This was a cross-sectional study conducted on a 
stratified non-random sample. It was conducted in 
the period from July 2010 to April 2013. The study 
has been approved by the Local Ethics Committee 
of the Department of Pediatrics, Ain shams 
university. An informed consent was taken from the 
parents/caregivers before enrollment. All the 
subjects had received wP vaccine according to the 
Expanded Program of Immunization (EPI) adopted 
by the Egyptian Ministry of Public Health. 
 
Study population: 
The studied sample included 500 healthy subjects 
who were consecutively enrolled within the 
following groups 
 
I. Mother-neonate pairs:  
These were 75 healthy full-term newly born babies 
and their mothers enrolled consecutively from the 
Department of Gynecology and Obstetrics, Ain 
Shams University. 
Inclusion criteria: 
• Term pregnancy [37 weeks to 41 weeks according 
to the American college of obstetrics and 
gynecology definition].9  
• Neonates with Apgar scores above 7 at one and 
five minutes  
Exclusion criteria: 
• Any maternal obstetric complication or chronic 
illness  
• Intrauterine growth retardation 
• Perinatal asphyxia 
 
II. Infants group: it included 100 healthy infants 
whose ages ranged between 2 and 4 months.  
III. Preschool children group: it included 90 
children. Their ages ranged between 2 and 6 
years.  
IV. School-aged children group: it included 80 
children whose ages ranged between 6 and 12 
years. 
V. Adolescent group: it included 80 adolescents 
whose ages ranged between 12 and 18 years. 
The groups of infants, children and adolescents 
were recruited from the Casualty and Orthopedic 
Outpatient Clinic of the Children's Hospital, Ain 
Shams University and the Primary Health Care Unit 
in Obour City, Great Cairo Province. 
Inclusion criteria: 
• Healthy appearing subjects 
• Normal growth patterns according to WHO 
standards  
Exclusion criteria: 
• Suspected primary or secondary immuno-
deficiency  
• Acute illness especially with fever and/or cough 
• Any chronic illness. 
 
Study Measurements: 
I. Clinical evaluation: 
For the mother-neonate pairs; maternal clinical 
history was taken together with revising their 
obstetric medical records to exclude any chronic 
illness, intake of immunosuppressive medications 
or any acute obstetric illness or perinatal asphyxia. 
Assessment of the neonates was done using the 
APGAR score to ensure neonatal wellbeing. 10 The 
enrolled infants, children and adolescents were 
assessed by history taking and physical examination 
to exclude acute/chronic illness especially primary 
or secondary immunodeficiency.11 WHO growth 
charts were used to assess growth.12 History 
suggestive of previously acquired whooping cough 
was sought for.  
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II. Serum pertussis specific IgG was estimated 
by an enzyme linked immunosorbent assay 
(ELISA): 
Two ml of venous blood were obtained by 
venipuncture from each participant and were 
collected into a gel vacutainer tube (Becton 
Dickinson, Oxford, UK). Blood was allowed to 
clot, and serum was separated by centrifugation 
(3500 rpm, 15 min, 25°C) and then stored in 
aliquots at     -20°C until used for quantitative 
detection of Bordetella pertussis IgG by using  
ELISA  kit (Bordetella pertussis IgG ELISA. I 
Blinternational Gmbh. IBL@IBL-International. 
com, Hamburg, Germany).The obtained OD (with a 
photometer at 450 nm) of the standards were 
plotted against their concentration on semi-
logarithmic graph paper. The concentration of the 
samples could be read directly from the standard 
curve. According to the manufacture instruction, 
the concentrations were interpreted as followed: < 




Data management and analysis were performed 
using Statistical Package for Social Sciences 
(SPSS) Version 21.0 (SPSS, Inc. Chicago III., 
USA) for Windows. Numerical data were 
summarized using means and standard deviations or 
medians and ranges as appropriate. Categorical data 
were summarized as percentages. Non normally  
distributed numeric variables were compared by 
Mann-Whitney test. For categorical variables, 
differences were analyzed with 2 (chi square) test 
and Fisher’s exact test when appropriate. 
Differences among three groups were analyzed with 
analysis of variance between groups (ANOVA) and 
Bonferroni post hoc test. Correlations were 
determined by using Pearson’s test or spearman 
Rho as appropriate. All p-values are two-sided. P-
values < 0.05 were considered significant. 
 
RESULTS 
The demographic, clinical and laboratory data of 
the studied sample are displayed in table 1.     
Positive pertussis IgG levels (>24 U/mL) were 
detected in 69 of the mothers (92%) and equivocal 
in the remaining six (8%), while positive pertussis 
IgG levels were present in 63 of the newborns 
(84%); 6 newborns (8%) had equivocal  levels and 
the remaining 6 (8%) did not have any pertussis 
IgG antibody titer (figure 1). Fifty-five subjects in 
the infants’ group (55 %) had positive pertussis IgG 
level; 7% had equivocal levels while the remaining 
38 infants (38%) were negative for pertussis IgG 
titer. Seroimmunity to pertussis was detected in 
82.2% of preschool children, 77.5% of school 
children and 75% in adolescents (figure 2). 
The rates of pertussis IgG seroimmunity and  
concentrations were significantly higher among the 
mothers as compared to the neonates (table 2). 
Also, serum pertussis IgG titers among the neonates 
showed a significant positive correlation with the 
maternal titers (P=0.0001) (figure 3).  
Mothers living in urban and suburban areas of 
Cairo had significantly higher serum pertussis IgG 
level than those living in rural areas such as the 
Sharkeya Governorate (Z=-2.83, p=0.005). Again, 
the children and adolescents living in urban and 
suburban areas had significantly higher frequency 
of seropositivity as compared to those living in 
rural areas (x2=6.1, p=0.04), but no significant 
difference was found  in  serum pertussis IgG 
concentrations between   urban and rural residents ( 
p>0.05). 
Our results did not vary with gender (p > 0.05). 
On the other hand,  serum pertussis IgG expression 
varied among the infants’ group being higher in 
infants aged 12-24 months than those who were 6 
months old by using the posthoc test,  (p=0.005). 
Nevertheless, comparable levels of serum pertussis 
IgG were found between infants aged from 6-12 
months and those aged less than 6 months. The 
preschoolers, school-aged children and adolescents 
showed comparable frequency of pertussis 
seroimmunity and IgG concentrations (p> 0.05). 
Also, in addition, there was no significant 
correlation between serum pertussis IgG titer and 
time elapsed after the last dose of pertussis vaccine 
whether in preschoolers, school-aged children or 


























 Age     
 Mean (SD) 8.6 (5.7) 3.5+1 8.8+1.4 14.2+1.4 
 Range 2 – 24 months 2-5.5 yrs. 6.5-11 yrs. 12.5-17 yrs. 
 Gender 
 n  (%) 










47 (58.8%)   
 Residence  
 n (%) 
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  Range 
 
7.7 (2) 
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Table 2. Pertussis seroimmunity and serum pertussis IgG titres among the mother-neonate pairs 
 
Mothers Neonates Test 
p 
value 




20 - 170 
56 (38) 
5 – 170 
t = -5.59 0.001 
Pertussis seropositivity n (%)     
 Positive 69 (92%) 63 (84%) X2 = 6.2 0.04 
 Equivocal 6 (8%) 6 (8%)   
 Negative 0 (0%) 6 (8%)   
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r = 0.694 
P= 0.00001 
Pertussis IgG titers in mothers 
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DISCUSSION 
In the current study, all subjects received the wP 
vaccine which is implemented in the schedule of 
compulsory vaccination of Egyptian children at 2, 
4, 6 and 18 months. A positive titre of serum 
pertussis IgG (>24U/mL) denoting seroimmunity 
was detected in 92% of the mothers, 84% of their 
newborns, 55% of the 2-24 months old infants, 82% 
of preschool children, 77.5% of school age 
children, and 75% of adolescents. The negative 
results among our sample may have resulted from 
failure of seroconversion after receiving the 
obligatory vaccine doses. Waning of immunity 
against pertussis could be an explanation for the 
negative results among older children and 
adolescents.  
It had been reported that the efficacy of 
diphtheria-tetanus-whole-cell pertussis (DTwP) 
vaccine ranges from 46% to 92%.13 Actually, the 
protective effect of the wP vaccine was reported to 
last for a varying period from 4-12 years in 
comparison to nearly 6 years of protection after 
acellular pertussis (aP) vaccine. 14,15  A study from 
Senegal, on children less than 15 years old, showed 
that three doses of a French wP vaccine had an 
overall efficacy of 55% against pertussis which is 
lower than our seroconversion rates.16 
Low or undetectable pertussis-related antibody 
levels (maternal anti-pertussis toxin (PT), 
filamentous hemagglutinin (FHA) and pertactin 
(PRN) IgG antibodies) were previously detected in 
parous women, suggesting increased susceptibility 
to infection. 17 Similarly, a previous study in Turkey 
reported that these anti-pertussis antibodies levels 
in cord and maternal blood in both preterm and 
term infant–mother pairs were generally inadequate 
to confer protection until the starting primary 
immunization. Transplacental anti-pertussis 
antibody transfer and antibody levels were reported 
to be inadequate in the cord blood of preterm 
infants, especially in those less than 32 weeks’ 
gestation.18 Several other studies reported low 
levels of protective pertussis antibodies in females 
during the child-bearing period.19-21  
This was not the case in our series where the 
high frequency of maternal seroimmunity against 
pertussis and the adequate serum pertussis IgG 
concentrations reflected a better immune status 
which is possibly achieved by the whole-cell 
vaccine usage and might be further enhanced by 
exposure to subclinical infection. 
The frequency of pertussis IgG seroimmunity 
and serum pertussis IgG concentrations were 
significantly higher among mothers as compared to 
the neonates in the current study. This is expected 
because transplacental antibody transfer may not be 
sufficient to confer the same rates of seroimmunity 
in the offspring. A previous study found that even 
with efficient transplacental passage of pertussis 
antibodies, neonates have limited measurable 
protection as detected by cord blood sampling.17 
However, the serum pertussis IgG titers of our 
group of neonates correlated positively to those of 
the mothers denoting that the higher the level of 
maternal seroimmunity, the higher the chance that 
her fetus acquires antibodies. The same conclusion 
was noted in previous studies.17, 22  
Among our series, subjects living in rural areas 
seemed to have less protective levels of pertussis 
IgG seroimmunity than their peers living in urban 
and suburban areas. This could be related to the 
degree of commitment of parents to the vaccination 
schedule in rural areas where lower parental 
education levels are expected. The efficacy of 
vaccine preservation and delivery might also differ 
according to residential classification.  
Gender did not influence the seroimmunity in 
our study; the same  was reported by several other 
investigators.23-26  
In the current study, serum pertussis IgG titres 
increased with age among the infants’ group being 
lowest below 6 months of age and higher in the 12 
to 24 months old which is expected due to the 
receival  of booster  doses of the vaccine. A 
relevant study showed that pertussis antibody levels 
>30 U/ml were observed with higher frequency in  
infants   younger than 2 years of age who 
completed the vaccination  schedule . 27 Another 
study revealed that vaccinated 1-2-year-old  infants   
and 17-18-year-old adolescents had the highest 
serum pertussis IgG titers. 24  
An interesting observation in a group of Turkish 
children was that pertussis antibodies increased 
after the age of 6 years and a further increase was 
observed between 7 and 12 years. Since there is no 
booster against pertussis at this age, this increase 
probably reflects the acquisition of natural 
immunity following the beginning of elementary 
school, where children join a new crowded 
community with higher rates of exposure to 
communicable diseases.25  
On the other hand, pertussis seroimmunity, 
among our series, did not vary significantly 
between preschoolers, school-aged children and 
adolescents. This finding needs to be further 
validated in wider scale studies although waning of 
immunity would be expected beyond these age 
groups.  The mean duration since the last dose of 
pertussis vaccine was 3, 8, and 13.5 years in the 
preschoolers, school-aged children, and adolescents 
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respectively. It has been reported that seroimmunity 
following pertussis vaccination offers a high degree 
of protection for 3 years after completion of infant 
immunization, but the vaccine antibodies begin to 
decrease 3-4 years after the last dose.28 Other 
investigational studies noted that pertussis vaccine 
antibodies start to wane after 4-12 years 8 or 6-9 
years.29  
 A previous study reported  that adolescents and 
older children are often the most affected by an 
outbreak of pertussis. Many adults may also 
become infected but may not develop significant 
symptoms. Vaccine-induced immunity seems to 
wane from childhood to adolescence but does not 
appear to wane further into adulthood. These 
findings suggest that adding an additional booster 
dose of acellular pertussis vaccine for adolescents 
may be helpful in further reducing the development 
of clinical disease in the community.30 
This pilot study has some limitations indeed. 
The relatively small sample size is inadequate to 
augment conclusions in a large population such as 
the Egyptian. Also, the uneven distribution of the 
sample according to residency hindered reaching a 
solid conclusion about the seroimmunity among 
rural residents. 
In conclusion, the subjects enrolled in the 
current study have relatively good pertussis 
seroimmunity rates and antibody titres that could be 
due to the use of whole cell vaccine in the national 
EPI schedule during the study period and possibly 
augmented by subclinical exposure to natural 
infection. The failure rates detected could be due to 
inefficient vaccination in the younger groups or 
waning of immunity in the older children and 
adolescents. The lower seroimmunity observed 
among rural residents might reflect a difference in 
vaccination efficiency or may be a false impression 
due to the smaller proportion of this sector among 
the studied sample. Wider scale studies would 
allow better insight into the Egyptian immune status 
against and hence the possible need for booster 
immunization. Also, investigating the cause of 
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